Impact of chronic graft-versus-host disease on quality of life and cognitive function of long-term transplant survivors after allogeneic hematopoietic stem cell transplantation with total body irradiation.

Abstract

BACKGROUND:

Total body irradiation (TBI)-based-conditioning before allogeneic hematopoietic stem cell transplantation (allo-HSCT) is standard of care in patients with acute myeloid leukemia (AML) but can cause long-term morbidity. Data on the impact of chronic Graft-versus-host disease (cGvHD) on cognitive function (CF) and quality of life (QoL) of long-term transplant survivors are sparse.

METHODS:

We analyzed patient-reported outcomes focusing on progression-free AML patients and 1st allo-HSCT applying a standardized TBI-technique with an average dose rate of 4 cGy/min to the total body and lung shielding in case of doses > 8 Gy. Instruments included the Functional Assessment of Cancer Therapy-Bone marrow transplant (FACT-BMT, version 4), the FACT-Cognition Function (FACT-Cog, version 3) and the Patient Health Questionaire-4 (PHQ-4). We put focus on the impact of cGvHD and compared the results to normative data derived from the general population.

RESULTS:

Out of 41 eligible patients contacted, 32 (78.0%) patients with a medium follow-up of 154 months (Interquartile range 113, 191 months) participated in the study. Eleven patients (34.4%) had active cGvHD, 11 (34.4%) resolved cGvHD and 10 (31.3%) never had cGvHD. Patients with active cGvHD had poorer FACT-BMT, FACT-Cog and higher PHQ-4 scores compared to patients with resolved cGvHD or who never had cGvHD. Outcomes were similar in patients with resolved cGvHD and those who never had cGvHD. Patients with active cGvHD had similar FACT-Cog, but lower FACT-BMT in comparison to normative data. However, the overall patient sample had similar FACT-BMT and FACT-Cog in comparison to normative data.

CONCLUSION:

Our data indicate that CF of long-term survivors upon TBI-based allo-HSCT is not impaired, even in the presence of active cGvHD. However, active cGvHD has a negative impact on QoL. Trial registration  The local Ethics Board of the University of Regensburg approved this study (Number 20-1810_1-101).

• Authors: Isabella Gruber, Oliver Koelbl, Wolfgang Herr, Ernst Holler, Matthias Edinger, Daniel Wolff
• Journal: Radiation oncology (London, England) (Radiat Oncol) Vol. 17 Issue 1 Pg. 195 (Nov 29 2022) ISSN: 1748-717X [Electronic] England
• PMID: 36447269 (Publication Type: Journal Article)
• Copyright: © 2022. The Author(s).

Topics

• Humans
• Cognition
• Graft vs Host Disease (etiology, radiotherapy)
• Hematopoietic Stem Cell Transplantation (adverse effects)
• Quality of Life
• Survivors
• Whole-Body Irradiation